Targeting IL-4 for the Treatment of Atopic Dermatitis

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ImmunoTargets and therapy Ročník 9; s. 151 - 156
Hlavní autoři: Chiricozzi, Andrea, Maurelli, Martina, Peris, Ketty, Girolomoni, Giampiero
Médium: Journal Article
Jazyk:angličtina
Vydáno: Macclesfield Dove Medical Press Limited 01.01.2020
Taylor & Francis Ltd
Dove
Dove Medical Press
Témata:
Advertising executives
Atopic dermatitis
B cells
Cytokines
Dendritic cells
Dermatitis
Dupilumab
Eczema
Gene expression
Granulocytes
il-4
il-4 inhibitor
Immune response
Immunotherapy
Inflammation
Interleukin 13
Interleukin 4
Interleukins
Kinases
Lymphocytes
Monoclonal antibodies
Neurons
pascolizumab
Pathogenesis
pitrakinra
Review
Skin
Skin diseases
ISSN:2253-1556, 2253-1556
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2253-1556
2253-1556
DOI:10.2147/ITT.S260370